JP2005513014A5 - - Google Patents

Download PDF

Info

Publication number
JP2005513014A5
JP2005513014A5 JP2003543603A JP2003543603A JP2005513014A5 JP 2005513014 A5 JP2005513014 A5 JP 2005513014A5 JP 2003543603 A JP2003543603 A JP 2003543603A JP 2003543603 A JP2003543603 A JP 2003543603A JP 2005513014 A5 JP2005513014 A5 JP 2005513014A5
Authority
JP
Japan
Prior art keywords
dosage unit
analog
range
present
suitable excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003543603A
Other languages
English (en)
Other versions
JP2005513014A (ja
JP4852229B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2002/011862 external-priority patent/WO2003041716A1/en
Publication of JP2005513014A publication Critical patent/JP2005513014A/ja
Publication of JP2005513014A5 publication Critical patent/JP2005513014A5/ja
Application granted granted Critical
Publication of JP4852229B2 publication Critical patent/JP4852229B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (9)

  1. 式(I)によって表されるプロスタグランジン(PG)アナログおよび/またはその互変異性体、および医薬上好適な賦形剤を含むヒト患者における便秘の軽減または予防に使用する用量単位であって、該PGアナログを約6−96μgの範囲で含有する用量単位:
    Figure 2005513014
    [式中、AおよびAは同一であっても異なっていてもよいハロゲン原子、および、
    Bは、−COOHであり、その医薬上許容される塩、エステルまたはアミドを含む]。
  2. PGアナログが式(I)の単環式互変異性体である、請求項1の用量単位。
  3. PGアナログが約24−72μgの範囲で存在する、請求項1の用量単位。
  4. PGアナログが約24−60μgの範囲で存在する、請求項3の用量単位。
  5. PGアナログが約48μg存在する、請求項4の用量単位。
  6. 医薬上好適な賦形剤が経口的に許容されるものである、請求項1の用量単位。
  7. 医薬上好適な賦形剤が中鎖脂肪酸である、請求項1の用量単位。
  8. およびAがフッ素原子である、請求項1の用量単位。
  9. Bが−COOHである、請求項8の用量単位。

JP2003543603A 2001-11-14 2002-11-14 便秘の処置用のプロスタグランジンアナログを含む用量単位 Expired - Lifetime JP4852229B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
US60/331,316 2001-11-14
PCT/JP2002/011862 WO2003041716A1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011117231A Division JP2011201905A (ja) 2001-11-14 2011-05-25 便秘の処置用のプロスタグランジンアナログを含む用量単位

Publications (3)

Publication Number Publication Date
JP2005513014A JP2005513014A (ja) 2005-05-12
JP2005513014A5 true JP2005513014A5 (ja) 2006-01-12
JP4852229B2 JP4852229B2 (ja) 2012-01-11

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003543603A Expired - Lifetime JP4852229B2 (ja) 2001-11-14 2002-11-14 便秘の処置用のプロスタグランジンアナログを含む用量単位
JP2011117231A Pending JP2011201905A (ja) 2001-11-14 2011-05-25 便秘の処置用のプロスタグランジンアナログを含む用量単位

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011117231A Pending JP2011201905A (ja) 2001-11-14 2011-05-25 便秘の処置用のプロスタグランジンアナログを含む用量単位

Country Status (15)

Country Link
US (3) US8097653B2 (ja)
EP (2) EP1443938B1 (ja)
JP (2) JP4852229B2 (ja)
AR (3) AR037524A1 (ja)
AT (1) ATE522218T1 (ja)
BR (1) BR0214075A (ja)
CA (1) CA2464420C (ja)
CY (1) CY1115856T1 (ja)
DK (2) DK1443938T3 (ja)
ES (2) ES2524369T3 (ja)
HK (1) HK1155649A1 (ja)
LU (1) LU92826I2 (ja)
PT (2) PT1443938E (ja)
TW (1) TWI331920B (ja)
WO (1) WO2003041716A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
ATE539756T1 (de) * 2002-10-23 2012-01-15 Sucampo Ag Prostaglandinsubstanzen für die behandlung von fettsucht
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
KR101393944B1 (ko) * 2006-01-24 2014-05-12 수캄포 아게 연질-젤라틴 캡슐 제형물
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
EP0503887B1 (en) * 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
EP0554794B1 (en) * 1992-02-04 1998-07-29 Eisai Co., Ltd. Aminobenzoic acid derivatives
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0857718T3 (da) * 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
PT978284E (pt) 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
AR026046A1 (es) * 1999-10-15 2002-12-26 R Tech Ueno Ltd NUEVA COMPOSICIoN Y MÉTODO PARA ESTABILIZAR LA MISMA
CA2404767C (en) 2000-04-06 2010-12-07 Sucampo Ag Bile secretion promoting composition containing a 15-keto prostaglandin
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
NZ529406A (en) 2001-05-18 2005-09-30 Sucampo Ag Halogenated prostaglandin derivatives for treating constipation and cleansing the gastrointestinal tract
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物

Similar Documents

Publication Publication Date Title
JP2005513014A5 (ja)
JP2003531118A5 (ja)
JP2005533860A5 (ja)
JP2006182786A5 (ja)
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
JP2004508410A5 (ja)
EP1797878A3 (en) Benzothiazole derivatives
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2007176958A (ja) セチリジン及びプソイドエフェドリンを含む錠剤
JP2003503449A5 (ja)
CA2464420A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2004505036A5 (ja)
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
JP2004532828A5 (ja)
JP2001520994A5 (ja)
JP2002509164A5 (ja)
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
JP2002542281A (ja) あらゆる気分障害、適応障害または不安−抑うつ混合障害の治療または予防に有用な医薬の調製のためのサレドゥタントおよび医薬として許容されるその塩類の使用
JP2005524666A5 (ja)
JPH02233613A (ja) ピペリジノアルカノール誘導体類用の液体製剤組成物
JP2004514709A5 (ja)
JP2005515155A5 (ja)
JP2004512376A5 (ja)